Barcha huquqlar himoyalangan.
0.00
0.00 (0.00%)
In the latest trading session, Astrazeneca (AZN) closed at $188.42, marking a +2.74% move from the previous day.
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakimab. The UK-based pharmaceutical company said the drug candidate met its primary objective in two Phase 3 studies, OBERON and TITANIA, marking a significant milestone in its respiratory pipeline.
AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.
Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, AstraZeneca said.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Toz.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard on a subdued Friday session, after its experimental COPD treatment tozorakimab succeeded in two late-stage clinical trials. The results mark the first positive phase III readout from a programme of more than 20 major data releases AstraZeneca expects to deliver in 2026, each adding weight to the company's ambition to reach $80 billion in annual revenue by 2030.
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened, the company said.
There is no data to display
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important. To help brin.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. During its fifth year, AstraZeneca's ACT on Health Equity initiative will fund 47 nonprofit programs whose missions support the goal of ad.
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3 EPS ($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates.
